Roivant Sciences (NASDAQ:ROIV – Get Free Report) and Orgenesis (NASDAQ:ORGS – Get Free Report) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability and valuation.
Profitability
This table compares Roivant Sciences and Orgenesis’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Roivant Sciences | -119.54% | -14.05% | -12.81% |
| Orgenesis | -3,827.81% | N/A | -130.18% |
Valuation & Earnings
This table compares Roivant Sciences and Orgenesis”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Roivant Sciences | $122.59 million | 62.34 | $4.35 billion | ($0.15) | -71.40 |
| Orgenesis | $662,000.00 | 20.57 | -$55.36 million | N/A | N/A |
Institutional & Insider Ownership
64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 22.6% of Orgenesis shares are held by institutional investors. 7.9% of Roivant Sciences shares are held by insiders. Comparatively, 5.7% of Orgenesis shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Risk and Volatility
Roivant Sciences has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500. Comparatively, Orgenesis has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for Roivant Sciences and Orgenesis, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Roivant Sciences | 0 | 1 | 5 | 1 | 3.00 |
| Orgenesis | 0 | 0 | 0 | 0 | 0.00 |
Roivant Sciences currently has a consensus price target of $18.08, suggesting a potential upside of 68.85%. Given Roivant Sciences’ stronger consensus rating and higher possible upside, research analysts plainly believe Roivant Sciences is more favorable than Orgenesis.
Summary
Roivant Sciences beats Orgenesis on 12 of the 13 factors compared between the two stocks.
About Roivant Sciences
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.
About Orgenesis
Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.
Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
